Prosecution Insights
Prosecution Insights
4 pending office actions • 3 art units • 3 examiners • 0 of 4 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 4 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 4 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (25%) |
| §112 only | 1 (25%) |
| No statute on record | 2 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BURKHART, MICHAEL D | 2 | 62.4% | +10.9% |
| ROBINSON, HOPE A | 1 | 67.9% | +43.2% |
| SINGH, SATYENDRA K | 1 | 60.8% | +67.1% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18068004 | BACTERIA ENGINEERED TO REDUCE HYPERPHENYLALANINEMIA | ROBINSON, HOPE A | 98d overdue |
| 17798586 | RECOMBINANT BACTERIA ENGINEERED TO TREAT DISEASES ASSOCIATED WITH METHIONINE METABOLISM AND METHODS OF USE THEREOF | SINGH, SATYENDRA K | 91d overdue |
| 18326637 | MICROORGANISMS PROGRAMMED TO PRODUCE IMMUNE MODULATORS AND ANTI-CANCER THERAPEUTICS IN TUMOR CELLS | BURKHART, MICHAEL D | 43d overdue |
| 18537897 | BACTERIA ENGINEERED TO TREAT A DISEASE OR DISORDER | BURKHART, MICHAEL D | 16d |
| Art Unit | Apps |
|---|---|
| 1638 | 2 |
| 1652 | 1 |
| 1657 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18537897 | BACTERIA ENGINEERED TO TREAT A DISEASE OR DISORDER | BURKHART, MICHAEL D | 1638 | Other | Non-Final OA | 16d | Pending | Dec 13, 2023 |
| 18326637 | MICROORGANISMS PROGRAMMED TO PRODUCE IMMUNE MODULATORS AND ANTI-CANCER THERAPEUTICS IN TUMOR CELLS | BURKHART, MICHAEL D | 1638 | §112 | Non-Final OA | 43d overdue | Pending | May 31, 2023 |
| 18068004 | BACTERIA ENGINEERED TO REDUCE HYPERPHENYLALANINEMIA | ROBINSON, HOPE A | 1652 | Other | Non-Final OA | 98d overdue | Pending | Dec 19, 2022 |
| 17798586 | RECOMBINANT BACTERIA ENGINEERED TO TREAT DISEASES ASSOCIATED WITH METHIONINE METABOLISM AND METHODS OF USE THEREOF | SINGH, SATYENDRA K | 1657 | §103 | Non-Final OA | 91d overdue | Pending | Aug 10, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial